--- title: "Top Biotech Stocks To Watch Today - September 13th" type: "News" locale: "en" url: "https://longbridge.com/en/news/298835668.md" description: "MarketBeat identifies Moderna, AbbVie, Amgen, Danaher, and Gilead Sciences as top biotech stocks to watch on September 13th. These companies were selected based on having the highest dollar trading volume among biotech stocks in recent days. The report highlights their key products and therapeutic areas, noting that while biotech stocks offer growth potential, they carry risks from clinical trials and regulatory decisions." datetime: "2026-09-13T16:01:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298835668.md) - [en](https://longbridge.com/en/news/298835668.md) - [zh-HK](https://longbridge.com/zh-HK/news/298835668.md) generator: "portal-rs" --- # Top Biotech Stocks To Watch Today - September 13th - Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Moderna, AbbVie, Amgen, Danaher, and Gilead Sciences are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop products and technologies based on biology, such as pharmaceuticals, vaccines, gene therapies, and diagnostic tools. For investors, these stocks can offer significant growth potential but often carry high risks because of clinical-trial outcomes, regulatory decisions, research costs, and uncertain product demand. These companies had the highest dollar trading volume of any Biotech stocks within the last several days. ## Moderna (MRNA) Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. - MarketBeat Week in Review – 08/17 - 08/21 Read Our Latest Research Report on MRNA ## AbbVie (ABBV) AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. - Moderna’s 177% Surge Has Investors Asking What Comes Next Read Our Latest Research Report on ABBV ## Amgen (AMGN) Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Read Our Latest Research Report on AMGN ## Danaher (DHR) Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. Read Our Latest Research Report on DHR ## Gilead Sciences (GILD) Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. Read Our Latest Research Report on GILD ## Recommended Stories - MarketBeat's Top Five Stocks to Own in September 2026 - Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound - 3 Small-Cap Biotechs With Binary Catalysts on the Calendar - Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound - As Homeowners' Premiums Surge, This Insurer Is Posting Record Profits - Nasdaq’s $100 Million Kraken Bet Prepares It for a Market That Never Closes *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Moderna Right Now? Before you consider Moderna, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list. While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [DHR.US](https://longbridge.com/en/quote/DHR.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md) ## Related News & Research - [Promising Biotech Stocks To Keep An Eye On - September 12th](https://longbridge.com/en/news/298811794.md) - [Moderna CFO James M. Mock disposes of 34,836 common shares worth $4.68 million](https://longbridge.com/en/news/298959314.md) - [AbbVie (ABBV) Just Gave Investors Something To Think About](https://longbridge.com/en/news/298537773.md) - [Saudi Central Bank Has $31.16 Million Stock Holdings in AbbVie Inc. $ABBV](https://longbridge.com/en/news/298802740.md) - [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**